Chiasma Inc. (CHMA)

5.71
0.22 4.01
NASDAQ : Health Technology
Prev Close 5.49
Open 5.47
Day Low/High 5.40 / 5.93
52 Wk Low/High 2.11 / 9.25
Volume 565.52K
Avg Volume 809.20K
Exchange NASDAQ
Shares Outstanding 41.95M
Market Cap 220.26M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Here's Why I Like These 2 High Risk/High Reward Small Caps

Here's Why I Like These 2 High Risk/High Reward Small Caps

I dub Resonant and Chiasma as 'busted IPOs'.

Chiasma Reports Second Quarter 2019 Results

Chiasma Reports Second Quarter 2019 Results

Announces positive data from Phase 3 CHIASMA OPTIMAL trial; MYCAPSSA ® NDA submission expected by year-end 2019 with an expected six-month PDUFA review time period MPOWERED enrollment complete; topline data expected in second half 2020 Completes common...

Chiasma To Report Second Quarter Financial Results On August 8, 2019

Chiasma To Report Second Quarter Financial Results On August 8, 2019

Company to host conference call and webcast at 5:00pm ET

Chiasma Announces Pricing Of Underwritten Public Offering Of $55.0 Million Of Common Stock

Chiasma Announces Pricing Of Underwritten Public Offering Of $55.0 Million Of Common Stock

WALTHAM, Mass., July 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc.

Chiasma Announces Proposed Offering Of Common Stock

Chiasma Announces Proposed Offering Of Common Stock

WALTHAM, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc.

Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa® For The Maintenance Treatment Of Adults With Acromegaly

Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa® For The Maintenance Treatment Of Adults With Acromegaly

SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who completed the 36-week study opted to continue into the Open Label Extension Company...

Chiasma Reports Fourth Quarter And Year End 2017 Results

Chiasma Reports Fourth Quarter And Year End 2017 Results

Chiasma Now Estimates Approximately 130 Patients Will Be Required to Enter Run-in Phase of MPOWERED Phase 3 Clinical Trial, Versus Previous Estimate of Up to 150 Patients

Chiasma Reports Second Quarter 2017 Results

Chiasma Reports Second Quarter 2017 Results

Anticipated release of top-line data from new OPTIMAL trial by end of 2019

Chiasma Appoints Roni Mamluk, Ph.D. To Board Of Directors

Longtime Chiasma Executive Also Assumes Director Role with Chiasma, Ltd, its Israeli Subsidiary

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Chiasma Announces Workforce Reduction

Chiasma Announces Workforce Reduction